These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 19816957)
1. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957 [TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635 [TBL] [Abstract][Full Text] [Related]
3. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188 [TBL] [Abstract][Full Text] [Related]
4. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143 [TBL] [Abstract][Full Text] [Related]
5. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217 [TBL] [Abstract][Full Text] [Related]
6. Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Navarro-Alvarez N; Kondo E; Kawamoto H; Hassan W; Yuasa T; Kubota Y; Seita M; Nakahara H; Hayashi T; Nishikawa Y; Hassan RA; Javed SM; Noguchi H; Matsumoto S; Nakaji S; Tanaka N; Kobayashi N; Soto-Gutierrez A Cell Transplant; 2010; 19(6):865-77. PubMed ID: 20587145 [TBL] [Abstract][Full Text] [Related]
7. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087 [TBL] [Abstract][Full Text] [Related]
9. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682 [TBL] [Abstract][Full Text] [Related]
10. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800 [TBL] [Abstract][Full Text] [Related]
11. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919 [TBL] [Abstract][Full Text] [Related]
12. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865 [TBL] [Abstract][Full Text] [Related]
13. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294 [TBL] [Abstract][Full Text] [Related]
14. Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells. Zhou J; Wang H; Cannon V; Wolcott KM; Song H; Yates C Mol Cancer; 2011 Sep; 10():112. PubMed ID: 21917149 [TBL] [Abstract][Full Text] [Related]
16. [Isolation and identification of cancer stem cells from primary human ovarian cancer tissues]. Lin S; Long HX; Xiang T; Zhu B; Xie RK Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):896-9. PubMed ID: 22340097 [TBL] [Abstract][Full Text] [Related]
17. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747 [TBL] [Abstract][Full Text] [Related]
18. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Guo R; Wu Q; Liu F; Wang Y Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969 [TBL] [Abstract][Full Text] [Related]
19. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Haraguchi N; Ohkuma M; Sakashita H; Matsuzaki S; Tanaka F; Mimori K; Kamohara Y; Inoue H; Mori M Ann Surg Oncol; 2008 Oct; 15(10):2927-33. PubMed ID: 18663533 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]